Literature DB >> 31375351

Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature.

Maria Giuseppa Vitale1, Cinzia Baldessari2, Michele Milella3, Sebastiano Buti4, Anna Maria Militello4, Stefania Di Girolamo5, Giuseppe Fornarini6, Gino Perri7, Umberto Basso8, Marco Maruzzo8, Camillo Porta9, Laura Cosmai10, Stefania Pipitone2, Krisida Cerma2, Stefano Cascinu2, Roberto Sabbatini2.   

Abstract

Entities:  

Keywords:  Dialysis; Immunotherapy; Kidney cancer; Metastatic renal cell carcinoma; Nivolumab

Mesh：

Substances：

Year:  2019        PMID： 31375351     DOI： 10.1016/j.clgc.2019.06.009

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  10 in total

1.  Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma.

Authors:  Hiroki Ishihara; Hironori Fukuda; Hidekazu Tachibana; Kazuhiko Yoshida; Hirohito Kobayashi; Toshio Takagi; Junpei Iizuka; Hideki Ishida; Yoji Nagashima; Tsunenori Kondo; Kazunari Tanabe
Journal:  Clin Exp Nephrol       Date:  2021-02-27       Impact factor: 2.801

2.  Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.

Authors:  Y Kobayashi; H Arai; M Honda
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

Review 3.  Use of Immune Checkpoint Inhibitors in End Stage Kidney Disease Patients, Single Center Experience and Review of the Literature.

Authors:  Jamie S Hirsch; Rimda Wanchoo; Jia H Ng; Yuriy Khanin; Kenar D Jhaveri
Journal:  Kidney360       Date:  2020-03-18

Review 4.  Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.

Authors:  Łukasz Mielczarek; Anna Brodziak; Paweł Sobczuk; Maciej Kawecki; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-25       Impact factor: 3.333

5.  Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice.

Authors:  Ming-Chun Kuo; Po-Jung Su; Chun-Chieh Huang; Hao-Lun Luo; Tai-Jan Chiu; Shau-Hsuan Li; Chia-Che Wu; Ting-Ting Liu; Yuan-Tso Cheng; Chih-Hsiung Kang; Yu-Li Su
Journal:  Front Oncol       Date:  2020-11-27       Impact factor: 6.244

6.  Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma.

Authors:  Takuya Iwaki; Aya Niimi; Masato Kano; Yoshiaki Kurokawa; Uran Yoshizaki; Keina Nozaki; Akira Nomiya; Hideyo Miyazaki; Haruki Kume
Journal:  IJU Case Rep       Date:  2020-10-28

7.  Use of Pembrolizumab in End-Stage Renal Disease: A Case Report with Complete Response.

Authors:  Marina Vitorino; Catarina Santos
Journal:  Case Rep Oncol       Date:  2022-03-10

Review 8.  Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis.

Authors:  Matteo Righini; Veronica Mollica; Alessandro Rizzo; Gaetano La Manna; Francesco Massari
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

Review 9.  Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?

Authors:  Umberto Maggiore; Alessandra Palmisano; Sebastiano Buti; Giulia Claire Giudice; Dario Cattaneo; Nicola Giuliani; Enrico Fiaccadori; Ilaria Gandolfini; Paolo Cravedi
Journal:  Transpl Int       Date:  2021-10-28       Impact factor: 3.842

Review 10.  Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

Authors:  Sheila Bermejo; Mónica Bolufer; Mar Riveiro-Barciela; Maria José Soler
Journal:  Front Med (Lausanne)       Date:  2022-06-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.